Paion AG (PA8)
XMUN 
Summary
PA8 Chart
Paion AG (PA8) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Paion AG ever had a stock split?
Paion AG Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Tilmann Bur CEO | XMUN Exchange | DE000A3E5EG5 ISIN |
| DE Country | 64 Employees | - Last Dividend | 12 Apr 2023 Last Split | - IPO Date |
Overview
Paion AG is a specialized pharmaceutical company focused on the development and commercialization of innovative drugs for use in hospital-based sedation, anesthesia, and critical care services around the globe. The firm boasts a product pipeline that includes a leading product, Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic designed for use in a variety of medical procedures. Founded in the year 2000 and headquartered in Aachen, Germany, Paion AG has established itself through strategic partnerships and licensing agreements with key players in the pharmaceutical industry such as Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. With its groundbreaking products, Paion AG aims to improve patient outcomes in critical care, anesthesia, and sedation, meeting the needs of a diverse range of medical professionals and their patients worldwide.
Products and Services
- Remimazolam
- Angiotensin II
- Eravacycline
This ultra-short-acting intravenous benzodiazepine sedative/anesthetic is Paion AG's flagship product. Currently, in clinical development, Remimazolam is being appraised for its efficacy and safety in procedural sedation, general anesthesia, and ICU sedation. Its main advantage lies in its rapid action and the ease with which its effects can be reversed, making it a promising option for various medical settings.
Angiotensin II represents a vasoconstrictor that Paion AG is developing for the specific indication of treating refractory hypotension in adults who are in septic or other forms of distributive shock. Its role in managing shock situations stems from its ability to rapidly increase blood pressure in critically ill patients, thereby potentially saving lives.
As a novel antibiotic agent under the fluorocycline class, Eravacycline has been indicated for the treatment of complicated intra-abdominal infections in adults. With antibiotic resistance on the rise, the development of Eravacycline showcases Paion AG's commitment to addressing urgent medical needs, offering a new solution to combat severe bacterial infections.
